A term of art used in clinical trials for the identification of the treatment code of a subject/patient or grouped results in studies where the treatment assignment was unknown to the subject and investigators.
Unlike the treatment with EGb, up to 90% of the patients given the Ch E inhibitors developed nausea and vomiting, so there is a suspicion that methodological reasons in the sense of an "unblinding" of the treatment groups caused the apparent superiority in the intensity of the effect.
On unblinding the dosing information, we observed that the adaptive Bayesian approach was able to identify 8 of the 20 patients during the drug-administration period for a drug without prior documentation of renal impairment.
Dobbs of the Institute of Psychiatry, King's College London, reported follow-up to a mean of 468 days after unblinding. The primary outcome measure was time trend in mean stride length at free-walking speed.
In placebo-controlled studies with synthetic antidepressants, experienced physicians can recognise the tell-tale side effects of these drugs, such as dry mouth, visual disturbances and dizziness, which arise in about 20% to 50% of patients and thus a degree of unblinding may occur.
Because of a low incidence of influenza infection (38/1559, 2.4%), the investigators combined the data before unblinding. Subjects were started on oseltamivir or placebo following an increase in influenzavirus activity at the clinical site.